MCID: KDN013
MIFTS: 31

Kidney Hypertrophy

Categories: Nephrological diseases

Aliases & Classifications for Kidney Hypertrophy

MalaCards integrated aliases for Kidney Hypertrophy:

Name: Kidney Hypertrophy 12 14
Hypertrophy of Kidney 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9622
ICD10 33 N28.81
ICD9CM 35 593.1
NCIt 47 C122991
SNOMED-CT 64 197800004 88531004
UMLS 69 C0156259

Summaries for Kidney Hypertrophy

MalaCards based summary : Kidney Hypertrophy, also known as hypertrophy of kidney, is related to screw worm infectious disease and hyperpigmentation of eyelid. An important gene associated with Kidney Hypertrophy is ALB (Albumin), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Nephrin/Neph1 signaling in the kidney podocyte. The drugs Azathioprine and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and prostate.

Related Diseases for Kidney Hypertrophy

Diseases related to Kidney Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 screw worm infectious disease 10.3 ALB CTGF
2 hyperpigmentation of eyelid 10.2 ALB ODC1
3 microcephaly 8, primary, autosomal recessive 10.2 ALB NPHS1
4 chronic inflammatory demyelinating polyradiculoneuropathy 10.1 ALB CTGF
5 renal hypoplasia 10.1 NPHS1 NPHS2
6 hypertrichosis of eyelid 10.0 CTGF NPHS2
7 cardiomyopathy, dilated, 1ee 10.0 NPHS1 NPHS2
8 vernal conjunctivitis 10.0 ALB CTGF
9 46xy sex reversal 8 10.0 NPHS1 NPHS2
10 congenital pulmonary alveolar proteinosis 10.0 NPHS1 NPHS2
11 female stress incontinence 10.0 NPHS1 NPHS2
12 hyperferritinemia-cataract syndrome 10.0 NPHS1 NPHS2
13 nephrotic syndrome, type 4 9.9 NPHS1 NPHS2
14 digestive system melanoma 9.9 NPHS1 NPHS2
15 retinitis pigmentosa 17 9.9 ALB CTGF NPHS1
16 patent foramen ovale 9.8 ALB CTGF
17 meacham syndrome 9.8 NPHS1 NPHS2
18 spastic monoplegia 9.8 ALB NPHS1 NPHS2
19 prostate neuroendocrine neoplasm 9.8 ALB NPHS1 NPHS2
20 nasopharyngeal carcinoma 2 9.7 ALB NPHS1 NPHS2
21 exocrine pancreatic insufficiency 9.7 ALB NPHS1 NPHS2
22 transient refractive change 9.7 ALB NPHS1 NPHS2
23 chronic myelomonocytic leukemia 9.7 ALB NPHS1 NPHS2
24 granuloma annulare 9.7 ALB NPHS1 NPHS2
25 gas gangrene 9.7 ALB NPHS1 NPHS2
26 hyperbiliverdinemia 9.6 CTGF NPHS1 NPHS2
27 inhibited male orgasm 9.6 ALB NPHS1 NPHS2
28 chronic pyelonephritis 9.5
29 pyelonephritis 9.5
30 bronchopneumonia 9.5
31 arteriosclerosis 9.5
32 uremia 9.5
33 calcinosis 9.4 ALB CTGF NPHS1 NPHS2
34 sarcocystosis 6.8 ALB ARAP1 CTGF NHEJ1 NPHS1 NPHS2

Comorbidity relations with Kidney Hypertrophy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Kidney Hypertrophy:



Diseases related to Kidney Hypertrophy

Symptoms & Phenotypes for Kidney Hypertrophy

Drugs & Therapeutics for Kidney Hypertrophy

Drugs for Kidney Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Everolimus Approved Phase 4,Phase 3,Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
5
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
6
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
7
Ticlopidine Approved Phase 4 55142-85-3 5472
8
Allopurinol Approved Phase 4 315-30-0 2094
9
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
10
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
11
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
12
Mycophenolic acid Approved Phase 4 24280-93-1 446541
13
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
14
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
15
Calcium Carbonate Approved Phase 4,Phase 3 471-34-1
16
Chlorthalidone Approved Phase 4 77-36-1 2732
17
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 1406-16-2
19
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
20
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1
23 Antifungal Agents Phase 4,Phase 3,Phase 1
24 Anti-Infective Agents Phase 4,Phase 3,Phase 1
25 Antimetabolites Phase 4
26 Antimetabolites, Antineoplastic Phase 4
27 Antirheumatic Agents Phase 4
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 1
29 diuretics Phase 4,Phase 2
30 Diuretics, Potassium Sparing Phase 4,Phase 2
31 Hormone Antagonists Phase 4,Phase 3,Phase 2
32 Hormones Phase 4,Phase 3,Phase 2
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
34 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2
35 Mineralocorticoids Phase 4,Phase 2
36 Natriuretic Agents Phase 4,Phase 2
37 Antihypertensive Agents Phase 4,Phase 3,Phase 2
38 Hypoglycemic Agents Phase 4,Phase 3
39 Antidepressive Agents Phase 4
40 Neurotransmitter Agents Phase 4,Phase 3
41 Neurotransmitter Uptake Inhibitors Phase 4
42 Psychotropic Drugs Phase 4
43
Serotonin Phase 4 50-67-9 5202
44 Serotonin Agents Phase 4
45 Serotonin Uptake Inhibitors Phase 4
46 Anticholesteremic Agents Phase 4
47 Atorvastatin Calcium Phase 4 134523-03-8
48 Calcium, Dietary Phase 4,Phase 3
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3
50 Hypolipidemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 112)

id Name Status NCT ID Phase Drugs
1 Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study Unknown status NCT02493465 Phase 4 Everolimus
2 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4 Spironolactone
3 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4 Optimal medical therapy
4 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
5 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
6 Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Completed NCT00688480 Phase 4 Placebo;Allopurinol
7 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4 Allopurinol;Placebo (for allopurinol)
8 Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease Completed NCT00548912 Phase 4 Spironolactone
9 EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure Completed NCT00338000 Phase 4 Epoetin alfa
10 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4 Surgical block (rocuronium; atracurium/mivacurium);Surgical block (rocuronium; atracurium/mivacurium)
11 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients Completed NCT01169701 Phase 4 Everolimus;Tacrolimus;Mycophenolic acid (MPA)
12 Parathyroidectomy in Endstage Renal Disease Completed NCT00745719 Phase 4
13 VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients Completed NCT00169910 Phase 4 AUC monitored withdrawal of MMF or CNI
14 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
15 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
16 Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Completed NCT00307463 Phase 4
17 A Clinical Trial of IntensiVE Dialysis Completed NCT00649298 Phase 4
18 Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis Completed NCT00413803 Phase 4
19 Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis Completed NCT00411177 Phase 4
20 Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD Active, not recruiting NCT02502981 Phase 4 Spironolactone;Chlortalidone
21 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Not yet recruiting NCT03182699 Phase 4
22 Active Vitamin D Effect on Left Ventricular Hypertrophy Terminated NCT00175149 Phase 4 Alfacalcidiol
23 A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen Terminated NCT02963103 Phase 4 Tacrolimus
24 CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression Withdrawn NCT01275352 Phase 4 Eplerenone;placebo
25 Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea Withdrawn NCT01861145 Phase 4 Nasonex
26 Vitamin D Supplementation and Cardiac Hypertrophy in Chronic Kidney Disease (CKD) Unknown status NCT01323712 Phase 2, Phase 3
27 Stenting of Renal Artery Stenosis in Coronary Artery Disease Study Unknown status NCT01173666 Phase 3 Medical therapy
28 Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Unknown status NCT02115659 Phase 3 Triptolide-Containing Formulation;Placebo
29 Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation Unknown status NCT01873352 Phase 3
30 The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 Completed NCT00497146 Phase 3 paricalcitol;placebo
31 The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease Completed NCT00446576 Phase 3 Epoetin Alfa
32 A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects. Completed NCT00364260 Phase 3 epoetin alfa
33 Effects of Somatostatin on ADPKD Heart Completed NCT02119013 Phase 2, Phase 3 Octeotride;Placebo
34 Iron Sucrose in Stage 3/4 Kidney Disease Completed NCT00202345 Phase 3 Iron sucrose
35 Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis Completed NCT00985322 Phase 3 ACE inhibitor Ramipril;non-RAS inhibitor antihypertensive therapy
36 Medical Therapy of Prostatic Symptoms (MTOPS) Completed NCT00021814 Phase 3 Doxazosin;Finasteride
37 Inflammatory Response to Salt in Essential Hypertension Completed NCT01665534 Phase 3
38 Effectiveness of Creatine Supplementation and Exercise on Muscle and Bone Completed NCT01057680 Phase 3
39 Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients Completed NCT00221845 Phase 3 ACE Inhibition;Intensified Blood Pressure Control;Add-on Angiotensin Receptor Blockade
40 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Completed NCT00663858 Phase 3 Cetrorelix 78+78;Cetrorelix 78 + Placebo
41 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3 Metformin
42 Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome Completed NCT00723801 Phase 3 Atenolol;Losartan
43 Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02055079 Phase 3 Sirolimus;Placebo
44 Lung Water by Ultrasound Guided Treatment in Hemodialysis Patients (The Lust Study). Recruiting NCT02310061 Phase 3
45 Hyperphosphatemia in Children With Chronic Kidney Disease Not yet recruiting NCT03202407 Phase 3 Calcium acetate and sevelamer hydrochloride
46 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 Terminated NCT00616902 Phase 3 paricalcitol injection 4 mcg/mL;Placebo Injection 4 mcg/mL
47 Hypertension in Hemodialysis Patients (Aim 3) Terminated NCT00582114 Phase 3 Lisinopril;Atenolol
48 Mineralocorticoid Receptor Antagonists in End Stage Renal Disease Unknown status NCT01691053 Phase 2 Spironolactone;Placebo
49 Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria Completed NCT00625820 Phase 2 6R BH4
50 Bosutinib For Autosomal Dominant Polycystic Kidney Disease Completed NCT01233869 Phase 2 Bosutinib;Bosutinib;Placebo

Search NIH Clinical Center for Kidney Hypertrophy

Genetic Tests for Kidney Hypertrophy

Anatomical Context for Kidney Hypertrophy

MalaCards organs/tissues related to Kidney Hypertrophy:

39
Kidney, Heart, Prostate, Lung, Bone, Endothelial, Brain

Publications for Kidney Hypertrophy

Articles related to Kidney Hypertrophy:

(show all 23)
id Title Authors Year
1
Correlation of whole kidney hypertrophy with glomerular over-filtration in live, gender-mismatched renal transplant allografts. ( 27576505 )
2016
2
Stimulation of Sigma-1 receptor by dehydroepiandrosterone ameliorates hypertension-induced kidney hypertrophy in ovariectomized rats. ( 20404054 )
2010
3
Development of hypertension and kidney hypertrophy in transgenic mice overexpressing ARAP1 gene in the kidney. ( 16801480 )
2006
4
The juvenile three-spined stickleback (Gasterosteus aculeatus L.) as a model organism for endocrine disruption II--kidney hypertrophy, vitellogenin and spiggin induction. ( 15588642 )
2004
5
Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. ( 15526251 )
2004
6
Effect of ammonium chloride and dietary phosphorus in the azotaemic rat. Part II--Kidney hypertrophy and calcium deposition. ( 15161952 )
2004
7
Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. ( 8603776 )
1996
8
An evaluation of the role of polyamines in different models of kidney hypertrophy in mice. ( 7474658 )
1995
9
Inhibition of renal ornithine decarboxylase activity fails to reduce kidney size and urinary albumin excretion in diabetic rats with manifest kidney hypertrophy. ( 7796931 )
1995
10
Renal proteinases and kidney hypertrophy in experimental diabetes. ( 7926340 )
1994
11
Inhibition of renal ornithine decarboxylase activity prevents kidney hypertrophy in experimental diabetes. ( 8447376 )
1993
12
Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. ( 1377139 )
1992
13
Morphometric analysis of kidney hypertrophy in rats after chronic potassium depletion. ( 1566879 )
1992
14
Vasopressin-dependent kidney hypertrophy: role of urinary concentration in protein-induced hypertrophy and in the progression of chronic renal failure. ( 2042645 )
1991
15
Characterization of beta-adrenergic receptor subtypes in androgen-induced mouse kidney hypertrophy using a new high-affinity ligand, [125I]iodocyanopindolol. ( 6299377 )
1983
16
Increased beta-adrenergic receptor complement in androgen-induced mouse kidney hypertrophy. ( 6269651 )
1981
17
Regulation of compensatory kidney hypertrophy by its own products. ( 894611 )
1977
18
The influence of salt intake on glomerular count in compensatory kidney hypertrophy in rats of different ages. ( 954972 )
1976
19
Ornithine decarboxylase activity and polyamine synthesis during kidney hypertrophy. ( 4119904 )
1972
20
Immunochemical studies on kidney hypertrophy of the rat. ( 13954727 )
1962
21
WEEKLY clinicopathological exercises: chronic pyelonephritis severe (with uremia); atrophy of the right kidney, hypertrophy of left; bronchopneumonia; aortic arteriosclerosis, severe, ascending arch, with short localized dissection; calcareous aortic stenosis. ( 14863577 )
1951
22
Kidney hypertrophy in B complex deficiency. ( 21024173 )
1946
23
THE PRODUCTION OF HYPERTENSION BY THE PREVENTION OF KIDNEY HYPERTROPHY: (Preliminary Report). ( 20321520 )
1939

Variations for Kidney Hypertrophy

Expression for Kidney Hypertrophy

Search GEO for disease gene expression data for Kidney Hypertrophy.

Pathways for Kidney Hypertrophy

Pathways related to Kidney Hypertrophy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.67 NPHS1 NPHS2 PODXL
2 10.37 NPHS1 NPHS2

GO Terms for Kidney Hypertrophy

Cellular components related to Kidney Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 slit diaphragm GO:0036057 8.8 NPHS1 NPHS2 PODXL

Biological processes related to Kidney Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 excretion GO:0007588 8.96 NPHS1 NPHS2
2 glomerular visceral epithelial cell development GO:0072015 8.62 NPHS1 PODXL

Molecular functions related to Kidney Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.28 ALB ARAP1 CTGF NHEJ1 NPHS1 NPHS2

Sources for Kidney Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....